Chemocentryx takes a leap of faith with avacopan
Despite the phase II failure, Chemocentryx is pushing on in hidradenitis suppurativa.
Key biotech catalysts approach
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
Important catalysts approach for smaller biotechs
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.
Chemocentryx soars on superior avacopan
With data showing superiority over glucocorticoids, Chemocentryx could have a new standard of care for vasculitis in avacopan.
Upcoming events – Rare disease data due from Chemocentryx and Sanofi
Chemocentryx and Sanofi are looking to target the complement pathway in ANCA-associated vasculitis and cold agglutinin disease respectively, with phase III data due in…
Small and mid-cap share price gains make up for majors
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.
